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Received January 25, 2013; accepted October 30, 2013AbstractBackground: Early neurological improvement has been observed in patients with stroke receiving treatment with standard intravenous re-
combinant tissue plasminogen activator. However, the effectiveness of thrombolytic treatment and the risk of hemorrhagic transformation are not
well understood in patients aged 80 years. In this study, we investigated the influence of age on early neurological improvement and hem-
orrhagic transformation rates in patients with stroke aged 80 years and receiving recombinant tissue plasminogen activator.
Methods: The study included 157 patients who received recombinant tissue plasminogen activator infusion at a teaching hospital. The National
Institutes of Health Stroke Scale was used to evaluate stroke severity. Early neurological improvement was defined as an improvement of 8 or more
points on this scale (compared with baseline) 24 hours after thrombolytic treatment. Neurological improvement was defined as an improvement of
8 or more points (compared with baseline) at discharge. Neurological deterioration was defined as an increase of 4 or more points (compared with
baseline). Multivariate analysis was used to evaluate the associations among age, neurological improvement, and hemorrhagic transformation.
Results: The rate of early neurological improvement was 36.9% (58/157 patients) and the rate of hemorrhagic transformation was 22.3% (35/157
patients). At discharge, the rate of neurological improvement was 50.9% (80/157 patients) and the rate of neurological deterioration was 13.4% (21/
157 patients). There was no statistically significant difference between patients aged80 years and those<80 years of age with respect to rates of
early neurological improvement, neurological deterioration, or hemorrhagic transformation. Among patients 80 years, the rate of neurological
improvement in those receiving thrombolytic treatment was higher than the rate in those patients not receiving thrombolytic treatment (58.8% vs.
14.1%, p < 0.01). We concluded that thrombolysis increases the rate of neurological improvement in patients aged 80 years.
Conclusion: In older patients, thrombolytic treatment increased the rate of neurological improvement compared with patients not receiving the
treatment. The study showed that thrombolytic treatment may be beneficial for patients 80 years, but should be performed with extreme care.
Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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In these patients, the goal of thrombolysis is to restore blood
flow in the occluded artery to prevent brain tissue damage
during reperfusion. Early neurological improvement (ENI) is
defined as an improvement in the National Institutes of Health
Stroke Scale (NIHSS) score of 8 or more points, or NIHSS
scores equal to 0 or 1 at 24 hours following rt-Pa infusion. One
study found that a higher ENI rate was observed in an rt-Pa
group than in a control group.2 The ENI rate is thought to
be related to the restoration of blood flow in the occludedociation. All rights reserved.
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hours,5 the response to thrombolysis is best evaluated after the
first 24 hours. Among female patients, blood glucose levels of
<8 mmol/L and the absence of cortical involvement are
associated with major neurological improvement and good
outcome at 3 months.6 Previous studies have reported that
intravenous infusion of rt-Pa in patients with stroke aged 80
years is associated with a lower probability of favorable
outcome, a higher mortality, and an increased rate of hemor-
rhage.7e9 However, other studies have shown that thrombol-
ysis induced by rt-Pa in patients with stroke aged 80 years is
both safe and beneficial.10,11 A report on the intravenous
infusion of rt-Pa in patients with stroke and cardiac myxoma
showed that higher hemorrhagic transformation (HT) and
lower response rates are observed in older patients.12 There-
fore whether or not the neurological response and HT rates are
related to age remain a matter of contention. This study was
conducted to investigate the influence of age on the rates of
ENI and hemorrhage.
2. Methods
Our data were drawn from the stroke registry database of a
teaching hospital in central Taiwan. We have regularly used rt-
Pa in patients with acute stroke since January 2007. The data
from all patients with stroke who received intravenous rt-Pa
treatment between January 2007 and December 2012 were
included in the study. All inclusion and exclusion criteria for
thrombolytic treatment were based on the guidelines for stroke
treatment in Taiwan, which state that patients 80 years of age
should not be given thrombolytic treatment.13 However, such
patients aged 80 years without other contraindications, who
arrived within 3 hours of the onset of stroke and requested
thrombolytic treatment, were given rt-Pa infusion. The group
not receiving rt-Pa included patients 80 years old who arrived
at our hospital within 3 hours of stroke onset without contra-
indications for thrombolytic treatment other than old age, but
who did not receive the treatment. Patients were followed-up
using computed tomography (CT) or magnetic resonance im-
aging (MRI) of the brain 24 hours after rt-Pa infusion.
The NIHSS scale was used to assess stroke severity. An
NIHSS-certified stroke team member at our facility performed
the scoring and evaluation after every 6 hours for the first 24
hours, and at discharge. ENI was defined as an improvementTable 1
Baseline characteristics of patients (n ¼ 157).
Age (y) n Male sex HTN DM Prior stroke AF
<80 140 87 103 (73.4) 51 (36.3) 19 (12.5) 50 (36
80 17 8 15 (92.8) 3 (7.10) 3 (21.4) 12 (71
p 0.24a 0.17a 0.71a <0.01
Data are presented as n (%).
AF ¼ atrial fibrillation; DM ¼ diabetes mellitus; HTN ¼ hypertension; NIHSS ¼ N
to recombinant tissue plasminogen activator infusion; SBP-pre ¼ systolic blood p
a Chi-square test or Fisher’s exact test.
b t test.of 8 points (compared with baseline) 24 hours after throm-
bolytic treatment, or an improvement in the NIHSS score of
0 or 1 towards the end of rt-Pa infusion. Neurological
improvement (NI) was defined as 8 point improvement
(compared with baseline) or an improvement in NIHSS score
of 0 or 1 at discharge.2 Neurological deterioration (ND) was
defined as a 4 point increase in the NIHSS score (compared
with baseline) at discharge.10 Early ND was defined as a 4
point increase in the NIHSS score (compared with baseline)
within 24 hours of rt-Pa infusion. HT was defined as any sign
of hemorrhage on the follow-up CT or MRI scans. Symp-
tomatic HT (SHT) was defined as blood clots in the brain
observed during follow-up CT or MRI scans, with an increase
in the NIHSS score of 4 or more points.14 The data used in the
study were collected from the Chia -Yi Christian Hospital
acute stroke registry. This registry has been approved by the
ethics committee of the hospital.
Statistical significance between the age groups was
analyzed using the Chi-square test or Fisher’s exact test for
categorical variables and t test for continuous parameters,
including NIHSS, blood pressure, and time from stroke onset
to rt-Pa infusion (rt-Pa time). Logistic regression analysis was
used to investigate the risk factors of HT and ENI. MedCalc
for Windows, version 12.3 (MedCalc Software, Ostend,
Belgium) was used for data analyses.
3. Results
From January 2007 to December 2012 in our hospital, 157
patients received intravenous rt-Pa for acute ischemic stroke
within 3 hours of stroke onset. Follow-up by MRI was per-
formed in 45.6% of these patients. During the 6-year study
inclusion period, 78 patients presented to our hospital within 3
hours of stroke onset and were considered eligible for
thrombolytic treatment (without contraindications for throm-
bolysis other than old age), but did not receive the treatment
because of their age (80 years). Follow-up by MRI was
performed in 60.2% of these patients. Of the patients who
received thrombolytic treatment, 140 were <80 years old
(younger group) and 17 were aged 80 years (older group).
Table 1 gives the baseline characteristics of the patients. The
baseline stroke severity was higher in patients aged 80 years
than in patients aged <80 years. The older age group patients
showed a higher prevalence of hypertension, atrial fibrillation,Heart disease SBP-pre
(mmHg)
Median
NIHSS score
Rt-Pa
time (min)
Smoker
.3) 67 (48.9) 155.7 14 113.8 57 (42.6)
.4) 14 (92.8) 156.3 22 112.8 6 (21.47)
a 0.12a 0.20b 0.001b 0.15b 0.79a
ational Institutes of Health Stroke Scale; Rt-Pa time ¼ time from stroke onset
ressure prior to thrombolysis.
Table 3
Stroke subtype and risk of hemorrhagic transformation (n ¼ 157).
Stroke
subtype
n Hemorrhage Odds ratio 95% CI p
CE 58 22 3.97 1.44e10.90 0.007
LAA 45 6 1
SVO 12 0 0.24 0.01e4.62 0.3
UE 42 7 1.30 0.39e4.24 0.7
CE ¼ cardioembolism; CI ¼ confidence interval; LAA ¼ large vessel disease;
SVO ¼ small vessel occlusion; UE ¼ undetermined etiology.
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infusion was not significantly different between the two
groups.
Twenty-four hours after intravenous rt-Pa infusion, ENI
was seen in 58/157 (36.9%) patients; this rate was not
significantly different between patients aged 80 years [9/17
(52.9%)] and those aged <80 years [49/140 (35%)] (p ¼ 0.18;
Table 2). HT was seen in 35/157 (22.3%) patients; the HT rate
was not significantly different between patients 80 years [5/
17(29.4%)] and those aged <80 years [30/140 (21.4%)]
(p ¼ 0.53; Table 2). SHT was observed in 10/157 (6.4%)
patients; SHT was not significantly different between patients
aged 80 years [2/17(11.7%)] and those aged <80 years [8/
140 (5.7%)] (p ¼ 0.29; Table 2). The stroke subtypes in the
157 patients were as follows: 57 cardioembolism, 45 large
vessel disease, 12 small vessel occlusion, and 43 of unknown
origin.15 Of the 35 patients with HT, 22 had cardiogenic ce-
rebral embolism, six had large vessel disease, and seven had
stroke of unknown origin. In comparison with large vessel
disease, cardiogenic cerebral embolism increased the risk of
HT with an odds ratio of 3.97 (Table 3). In four of the 35
patients with HT, the hemorrhage was located outside the main
stroke area; among these four patients, three were aged be-
tween 74 years and 80 years and one was 91 years old. Of the
four patients, two were of the cardioembolism stroke subtype
and two of an unknown origin. Followup by MRI was per-
formed in two of these four patients. However, there was no
significant change in the rates of HT between patients in the
younger and older age groups (p ¼ 0.53). At discharge, the NI
rate was 51.6% (81/157) in all patients and 58.8% (10/17) in
patients aged 80 years. The early ND rate was 14.1% (22/
157), which was not significantly different between the older
and younger groups (p > 0.99). The ND rate at discharge was
19.7% (31/157) in all patients and 11.7% (2/17) in patients
aged 80 years, which was not significantly different between
the older and younger groups (p ¼ 0.52). In patients aged 80
years who did not receive thrombolysis, the NI rate was 14.1%
(11/78) and the ND rate was 12.8% (10/78). In patients aged
80 years, the NI rate was significantly higher in the throm-
bolytic group than in the nonthrombolytic group (p < 0.01;
Table 4). There was no significant difference in the HT and
SHT rates between the thrombolytic and nonthrombolytic
groups (29.4% vs. 10.3%, p ¼ 0.09; 11.7% vs. 3.84%,
p ¼ 0.46; Table 4).
Fourteen of the 157 patients died during hospitalization and
the in-hospital mortality was 8.9%. However, none of these 14Table 2
Comparison of patient conditions after thrombolytic treatment between patients ag
Age (y) n Male sex ENI ICH
<80 140 87 49 (35.0) 30 (21.4)
80 17 8 9 (52.9) 5 (29.4)
Total
pa
157 95 58 (36.9)
0.18
35 (22.3)
0.53
Data are presented as n (%).
ENI ¼ early neurological improvement; early ND ¼ neurological deteriorat
ND ¼ neurological deterioration at discharge; NI ¼ neurological improvement at
a Chi-square or Fisher‘s exact test, where appropriate.patients was aged 80 years. Among these 14 patients, 11 had
middle cerebral artery occlusion and three had basilar artery
occlusion. Four of the 11 (36.4%) patients with middle cere-
bral artery occlusion showed HT.
4. Discussion
As thrombolysis with rt-Pa improves outcome in patients
after stroke, it has become a common practice in many clinics.
However, some medical centers do not recommend rt-Pa for
patients aged 80 years.13 This study was designed to inves-
tigate whether age affects the rates of ENI and HT in patients
treated with intravenous rt-Pa.
In this study, patients aged 80 years showed a higher
prevalence of hypertension, cardiovascular disease, and atrial
fibrillation compared with patients <80 years old. However,
this did not affect the rates of response and HT. The ENI rates
in 36.9% of patients observed in this study were close to those
observed in an earlier study by Saposnik et al,6 in which 28%
of patients showed higher rates of ENI. Furthermore, the rates
of ENI in our study are moderately higher than those reported
by Felberg et al,4 where 22% of patients showed early dra-
matic recovery. This difference may be because all patients in
the study of Felberg et al4 had middle cerebral artery
occlusion.
Mishra et al11 reported that elderly patients who underwent
thrombolysis treatment showed a better stroke outcome at 90
days compared with patients without thrombolysis. However,
in addition to thrombolysis, patient condition and quality of
patient care could play a part in this 90-day outcome. By
contrast, our study focused on ENI, which is only related to
the effect of thrombolysis and not the quality of patient care
after discharge. The results of our study indicate that rt-Pa
treatment may increase the rate of NI in older patients with
stroke.ed <80 years or 80 years (n ¼ 157).
SHT Early ND NI ND
8 (5.7) 20 (14.2) 70 (50.0) 29 (20.7)
2 (11.7) 2 (11.7) 10 (58.8) 2 (11.7)
10 (6.4)
0.29
22 (14.1)
> 0.99
80 (50.9)
0.61
31 (19.7)
0.52
ion within 24 hours of rt-Pa infusion; ICH ¼ intracranial hemorrhage;
discharge; SHT ¼ symptomatic hemorrhagic transformation.
Table 4
Comparison of baseline characteristics between treatment and non-treatment with recombinant tissue plasminogen activator in patients aged 80 years (n ¼ 95).
Rt-pa n Median
NIHSS score
DM HTN Prior stroke AF NI ND HT SHT
Yes 17 17.5 2 (11.2) 16 (94.1) 4 (23.5) 12 (70.5) 10 (58.8) 3 (17.6) 5 (29.4) 2 (11.7)
No
p
78 13
0.62b
16 (20.5)
0.62a
66 (84.6)
0.51a
22 (28.2)
0.92a
32 (44.1)
0.05a
11 (14.1)
0.007a
10 (12.8)
0.69a
11 (10.3)
0.09a
3 (3.84)
0.46a
Data are presented as n (%).
AF ¼ atrial fibrillation; DM ¼ diabetes mellitus; HT ¼ hemorrhagic transformation; HTN ¼ hypertension; ND ¼ neurological deterioration; NI ¼ neurological
improvement; NIHSS ¼ National Institutes of Health Stroke Scale; SHT ¼ symptomatic hemorrhagic transformation.
a Chi-square or Fisher‘s exact test, where appropriate.
b t test.
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years, patients aged 80 years did not have an increased risk
of SHT or HT after thrombolytic treatment. In addition, there
was no significant difference in the rate of ENI or NI in pa-
tients receiving thrombolytic treatment. However, in older
patients, thrombolytic treatment did not increase the risk of
HT or SHT compared with that of patients not receiving
thrombolytic treatment. Furthermore, in our study we noticed
higher HT rates among patients aged 50e59 years and 80
years. Moreover, because most HT occurred in patients with
total anterior circulation infarctions, we propose that the
hemorrhagic rate is not influenced by age, but primarily de-
pends on the type of stroke. After thrombolysis, four patients
aged >74 years developed brain hemorrhage outside the main
area of the infarct. This may be due to small cardioembolism
or microaneurysm, which was undiagnosed in CT scans of the
brain.16
Patients with stroke and atrial fibrillation have a higher risk
of mortality and intracerebral hemorrhage.17 In our study, the
cerebral hemorrhage rate among patients aged 80 years not
receiving thrombolysis was 10.3%; this is higher than that
reported by Frank et al,18 and lower than that of Lee et al.19
The study by Frank et al18 reported intracranial hemorrhage
in 2.7% of patients with stroke without atrial fibrillation, and
3% of patients with atrial fibrillation.18 The study of Lee
et al,19 by contrast, reported intracerebral hemorrhage in 15%
of patients.
HT after thrombolytic treatment occurred in 35(22.3%)
patients. Of note, 10 (6.4%) patients displayed SHT. The HT
and SHT rates were lower than those reported by Bang
et al,20 who found HT in 46.4% and SHT in 18.9% of pa-
tients who received intra-arterial thrombolysis. The lower
HT rate observed in our study may be partly caused by the
fact that only 6.8% (3/44) of the patients with atrial fibril-
lation regularly took anticoagulant drugs prior to their
stroke.
Our study has certain limitations. Firstly, our data were
based on regular clinical practice registration and not on
randomized trials. Secondly, the guidelines in Taiwan for
using rt-Pa in patients with stroke aged 80 years may have
caused a selection bias. Thirdly, we did not perform routine
follow-up cerebral imaging for the detection of hemorrhage in
patients who were not treated by thrombolysis, which
may have resulted in an underestimation of the hemorrhagic
rate.In conclusion, thrombolysis did not decrease the rates of
ENI or HT in older patients with stroke compared with pa-
tients in other age groups. In older patients, thrombolysis may
result in an increase in the NI rate compared with that in older
patients not receiving thrombolysis. This study showed that
thrombolysis in patients aged 80 years may have a beneficial
outcome when performed with extreme care.
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